Pancreatic Cancer: New Daily Pill Shows Promise in Shrinking Tumours

Pancreatic Cancer: New Daily Pill Shows Promise in Shrinking Tumours

A new daily pill, daraxonrasib, is raising hopes in pancreatic cancer treatment after early trials showed tumour shrinkage and undetectable cancer in some patients, although doctors say longer-term studies remain essential.

A new daily pill is raising hopes of a major breakthrough in pancreatic cancer treatment, with early clinical trial results showing that it can shrink tumours and potentially make them undetectable in some patients with the deadly and difficult-to-treat disease.

In early medical trials, one in every 12 patients who received daraxonrasib alongside chemotherapy had no detectable signs of cancer on their scans.

Almost all of the 61 patients involved in the trial experienced a halt in tumour growth. All had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.

However, doctors have cautioned that it is still unclear how long the drug can control the disease. They have stressed that it should not be considered a cure or a treatment that can completely eliminate cancer.

Read More Agra Air Pollution: AQI Crosses 400 as Hospitals See Surge in Patients

Cancer Research UK has described the development as the biggest advance in pancreatic cancer treatment in decades.

Read More Thane Government Schools, Hospitals to Get ₹550 Crore Makeover by January 2028

Dr Sam Godfrey of Cancer Research UK told BBC News that the findings were extremely encouraging.

Read More Sewage Surveillance: India Sets 48-Hour Reporting Rule to Detect Disease Outbreaks Early

"This new drug has found a way to control with medication something that was previously considered impossible to control with drugs," he said.

"At last, we are seeing progress in pancreatic cancer treatment, something that has been needed for a long time," he added.

Pancreatic cancer is considered one of the most difficult cancers to treat. In the UK, it has the lowest survival rate among all common types of cancer.

Although chemotherapy can reduce tumour size to some extent, the cancer often starts growing again. Most patients with advanced pancreatic cancer survive for only a few months rather than years.

Doctors hope the new treatment could give patients more time, even if it cannot eliminate the disease permanently.

Patients in the trial were monitored for an average of 18 months. During this period, some showed no signs of their cancer returning.

However, longer-term studies will be needed to establish whether the cancer in these patients can enter remission and how long that remission might last.

The results of the Phase 1 and Phase 2 trials showed that tumour growth was halted in 90% of patients. Slightly more than 60% experienced a reduction in tumour size or saw their tumours disappear. Around 8% of patients, equivalent to approximately one in every 12, had no detectable tumours on their CT scans.

Dr Vungki Park of Memorial Sloan Kettering Cancer Center in the United States was also involved in the trial. He described the results so far as extremely encouraging.

"We are seeing not only an increase in the proportion of patients whose tumours respond to treatment, but also a significantly greater impact from the treatment. The duration for which the disease remains under control has also almost doubled. This could increase the chances of patients surviving for longer in the future," he said.

Daraxonrasib is a targeted inhibitor drug that has already received approval in the United States. It works against certain mutations in a protein family known as RAS, preventing them from becoming active.

These mutations are found in most pancreatic cancers and are responsible for driving tumour growth.

Similar mutations can also occur in several other cancers, including lung and ovarian cancer. This raises the possibility that the drug could also benefit patients suffering from other forms of cancer.

Dr Godfrey said he hoped the early success seen in pancreatic cancer could eventually be applied to the treatment of other cancers as well.

He emphasised that longer-term trials and their findings would be crucial.

"Cancer can return. The fact that scans show no signs of it does not mean you are completely cancer-free. More time needs to pass before that can be established," he said.

Professor Elena Garralda, chair of the European cancer conference EORTC-NCI-AACR Symposium 2026, also described the findings as encouraging.

She said, "These results are encouraging because they suggest that using both treatments together could increase patients' overall survival. They could also extend the time before tumours start growing again."

The research is being presented to doctors at the conference.

In the United States, pancreatic cancer accounts for approximately 3% of all cancer cases but is responsible for around 8% of all cancer-related deaths. The disease claims approximately 53,000 lives every year.

According to Cancer Research UK, around 11,500 cases of pancreatic cancer are diagnosed in the UK every year, while approximately 10,200 people die from the disease annually.

Actor Alan Rickman also died from pancreatic cancer in 2016. He passed away five months after being diagnosed with the disease.

Symptoms of pancreatic cancer can include jaundice, itchy skin, dark-coloured urine, pale-coloured stools, unexplained weight loss, fatigue and a high fever.

Although the early findings offer fresh hope for patients facing one of the most challenging forms of cancer, doctors have emphasised that further research and long-term monitoring will be essential to determine whether daraxonrasib can deliver lasting disease control and improve survival.

Tags:

About The Author

Post Comment

Comment List

Latest News

Pancreatic Cancer: New Daily Pill Shows Promise in Shrinking Tumours Pancreatic Cancer: New Daily Pill Shows Promise in Shrinking Tumours
A new daily pill, daraxonrasib, is raising hopes in pancreatic cancer treatment after early trials showed tumour shrinkage and undetectable...
Delimitation Bill: Congress Claims PM Modi, Amit Shah Seek Two-Thirds Majority
PM Modi's Lucknow Visit Today: 4,400 Police Personnel Deployed for Security

Live Cricket Score

Advertisement

Science & Tech

Hero Flex Fuel Bikes Cross 15,000 Sales in Just Over Two Months in India Hero Flex Fuel Bikes Cross 15,000 Sales in Just Over Two Months in India
Hero MotoCorp's flex-fuel bikes have crossed 15,000 sales in just over two months. Running on E85 petrol priced at Rs...
GTA 6 Launch Fever: Gamers Take Leave, Millions Preorder as Hype Peaks

Health

Pancreatic Cancer: New Daily Pill Shows Promise in Shrinking Tumours Pancreatic Cancer: New Daily Pill Shows Promise in Shrinking Tumours
A new daily pill, daraxonrasib, is raising hopes in pancreatic cancer treatment after early trials showed tumour shrinkage and undetectable...
Sugar Cravings Explained: What Your Body May Be Telling You About Your Health

Lifestyle

5 Homemade Detox Drinks That May Help Keep Your Body Hydrated and Refreshed 5 Homemade Detox Drinks That May Help Keep Your Body Hydrated and Refreshed
Discover 5 easy homemade detox drinks made with cucumber, lemon, ginger, mint, carrot and coconut water. Learn how these refreshing...
Pet Parenting Trend Rises in India as Young Couples Spend Thousands on Dogs
crossorigin="anonymous">